Extract of <span class='bold-italic'>Ginkgo biloba</span> Treatment for Tardive Dyskinesia in Schizophrenia: A Randomized, Double-Blind, Placebo-Controlled Trial
J Clin Psychiatry 2011;72(5):615-621
© Copyright 2017 Physicians Postgraduate Press, Inc.
Purchase This PDF for $40.00
If you are not a paid subscriber, you may purchase the PDF.
(You'll need the free Adobe Acrobat Reader.)
Receive immediate full-text access to JCP. You can subscribe to JCP online-only ($86) or print + online ($156 individual).
With your subscription, receive a free PDF collection of the NCDEU Festschrift articles. Hurry! This offer ends December 31, 2011.
If you are a paid subscriber to JCP and do not yet have a username and password, activate your subscription now.
As a paid subscriber who has activated your subscription, you have access to the HTML and PDF versions of this item.
Click here to login.
Did you forget your password?
Still can't log in? Contact the Circulation Department at 1-800-489-1001 x4 or send email
Objective: Free radicals may be involved in the pathogenesis of tardive dyskinesia (TD). Extract of Ginkgo biloba (EGb) is a potent antioxidant possessing free radical–scavenging activities. The aim of the study was to evaluate the efficacy of EGb-761, a standardized extract given in capsule form, in treating TD in schizophrenia patients.
Method: Inpatients with DSM-IV–diagnosed schizophrenia and TD (n = 157) in a mainland China Veterans Affairs psychiatric hospital were randomly assigned to 12 weeks of treatment with either EGb-761, 240 mg/d (n = 78) or a placebo (n = 79) in a double-blind manner. Primary outcome measures were (1) change from baseline in the Abnormal Involuntary Movement Scale (AIMS) score and (2) proportion of patients with a ≥ 30% reduction in their AIMS total score at week 12. Secondary outcome measures included the Positive and Negative Syndrome Scale (PANSS) and cognitive performance as measured by the Continuous Performance Test-37 Version and the 3-card Stroop task. Patients were recruited for the study between December 2006 and May 2007.
Results: Of the 157 patients who were randomly assigned, 152 (96.8%) completed the study. EGb-761 treatment significantly decreased the AIMS total score in patients with TD compared to those who were given a placebo (2.13 ± 1.75 vs −0.10 ± 1.69; P < .0001), with 40 (51.3%) and 4 (5.1%) patients achieving response in the EGb-761 and placebo treatment groups, respectively. There were no between-group differences in the PANSS total score or cognitive measures from baseline to week 12.
Conclusions: EGb-761 appears to be an effective treatment for reducing the symptoms of TD in schizophrenia patients, and improvement may be mediated through the well-known antioxidant activity of this extract.
Trial Registration: clinicaltrials.gov identifier: NCT00672373
J Clin Psychiatry
Submitted: February 10, 2009; accepted October 29, 2009.
Online ahead of print: September 21, 2010 (doi:10.4088/JCP.09m05125yel).
Corresponding author: Dong-Feng Zhou, MD, Institute of Mental Health, Peking University, No. 51 Hua Yuan Bei Rd, Hai Dian District, Beijing 100191, China (email@example.com); or Xiang-Yang Zhang, PhD, Center for Biological Psychiatry, Beijing Hui-Long-Guan Hospital; De Sheng Men Wai Rd, Chang Ping District, Beijing 100096, China (firstname.lastname@example.org).